BMJ journal deems opioid dependency implant more favourable than tablets
While the opioid epidemic in the USA is well documented, Europe also has an estimated 1.3 million high-risk opioid users.
Read More
Tag: opioid
Opioid analgesics, Z-drugs linked to harmful effects in dementia patients
Medicines commonly prescribed to dementia patients have been linked to an increase in harmful side-effects, according to new research involving the University of Exeter and King’s College London.
Read More
‘Inappropriate’ painkiller prescribing shortened 456 lives at Gosport Hospital
More than 450 patients at Gosport War Memorial Hospital lost their lives early because they were inappropriately given powerful opioid analgesics, a public inquiry has concluded.
Read More
Study reveals stark North-South divide in opioid prescriptions
Researchers are calling for a national database of high opioid users after finding that the number prescriptions and related deaths in England is on the rise, especially in poorer communities.
Read More
EU nod for opioid dependence therapy
The European Medicines Agency has issued a marketing authorisation for Orexo and MundiPharma’s Zubsolv (buprenorphine and naloxone) for opioid dependence.
Read More
MundiPharma, Orexo file Zubsolv in Europe
UK-based MundiPharma and Swedish group Orexo’s have filed opioid dependence drug Zubsolv in Europe.
Read More
Pfizer’s abuse-deterrent opioid bags US nod
Pfizer’s Troxyca ER has been approved in the US for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Read More
Endo withdraws abuse-deterrent labelling for Opana ER
Dublin, Ireland-based speciality pharma Endo International is withdrawing its US application to add abuse deterrent labelling to its long-acting opioid Opana ER.
Read More
Pfizer’s abuse-resistant opioid nears US market
A US Food and Drug Administration advisory panel is recommending approval of Pfizer’s abuse-resistant opioid painkiller ALO-02.
Read More
SkyePharma buys access to abuse deterrent drug delivery tech
Skyepharma has bought itself access Lucideon’s abuse-deterrent drug delivery technology to use in the development of a new formulation of an undisclosed opioid.
Read More
FDA panel backs Teva’s new abuse-deterrent opioid
US Food and Drug Administration advisors have backed approval of Teva’s abuse-deterrent opioid Vantrela ER.
Read More
US OKs first implant for opioid addiction
US regulators have approved the first buprenorphine implant to help treat people addicted to opioids, including prescription painkillers and heroin.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
